$CPRX
Catalyst Pharmaceuticals Inc

2018 Q1 Form 10-Q Financial Statement

#000119312518157513 Filed on May 09, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue $0.00
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $2.674M $1.870M
YoY Change 43.02% -30.48%
% of Gross Profit
Research & Development $3.259M $2.814M
YoY Change 15.82% -20.65%
% of Gross Profit
Depreciation & Amortization $8.015K $12.96K
YoY Change -38.15% -1.82%
% of Gross Profit
Operating Expenses $5.933M $4.680M
YoY Change 26.79% -24.97%
Operating Profit -$5.933M -$4.680M
YoY Change 26.79% -24.97%
Interest Expense $0.00 -$400.0K
YoY Change -100.0% -154.79%
% of Operating Profit
Other Income/Expense, Net $233.5K $110.0K
YoY Change 112.36% -6.75%
Pretax Income -$5.700M -$4.967M
YoY Change 14.75% -7.78%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$5.700M -$4.967M
YoY Change 14.75% -7.78%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$55.58K -$59.90K
COMMON SHARES
Basic Shares Outstanding 102.6M shares 82.97M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q1 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $77.90M $36.50M
YoY Change 113.42% -30.48%
Cash & Equivalents $19.60M $9.981M
Short-Term Investments $58.30M $26.50M
Other Short-Term Assets $1.000M $1.000M
YoY Change 0.0% 0.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $78.94M $37.46M
YoY Change 110.74% -29.96%
LONG-TERM ASSETS
Property, Plant & Equipment $183.4K $231.2K
YoY Change -20.7% 29.66%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00
YoY Change
Total Long-Term Assets $192.3K $240.1K
YoY Change -19.94% 28.25%
TOTAL ASSETS
Total Short-Term Assets $78.94M $37.46M
Total Long-Term Assets $192.3K $240.1K
Total Assets $79.13M $37.70M
YoY Change 109.91% -29.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $805.0K $917.9K
YoY Change -12.3% -26.65%
Accrued Expenses $1.926M $987.6K
YoY Change 95.05% -30.07%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.731M $1.906M
YoY Change 43.34% -28.47%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $200.0K $700.0K
YoY Change -71.43% 40.0%
Total Long-Term Liabilities $200.0K $700.0K
YoY Change -71.43% 40.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.731M $1.906M
Total Long-Term Liabilities $200.0K $700.0K
Total Liabilities $2.882M $2.601M
YoY Change 10.8% -16.88%
SHAREHOLDERS EQUITY
Retained Earnings -$132.3M -$113.1M
YoY Change 16.93% 18.49%
Common Stock $102.6K $82.97K
YoY Change 23.64% 0.12%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $76.25M $35.10M
YoY Change
Total Liabilities & Shareholders Equity $79.13M $37.70M
YoY Change 109.91% -29.76%

Cashflow Statement

Concept 2018 Q1 2017 Q1
OPERATING ACTIVITIES
Net Income -$5.700M -$4.967M
YoY Change 14.75% -7.78%
Depreciation, Depletion And Amortization $8.015K $12.96K
YoY Change -38.15% -1.82%
Cash From Operating Activities -$6.081M -$3.880M
YoY Change 56.74% -34.57%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$31.85M -$30.00K
YoY Change 106066.67% -57.14%
Cash From Investing Activities -$31.85M -$30.00K
YoY Change 106058.98% -57.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 33.03K 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -6.081M -3.880M
Cash From Investing Activities -31.85M -30.00K
Cash From Financing Activities 33.03K 0.000
Net Change In Cash -37.90M -3.910M
YoY Change 869.21% -34.94%
FREE CASH FLOW
Cash From Operating Activities -$6.081M -$3.880M
Capital Expenditures $0.00
Free Cash Flow -$6.081M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
102586164 shares
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
102586164 shares
CY2018Q1 us-gaap Common Stock Value
CommonStockValue
102586
CY2018Q1 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
25597
CY2018Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
8888
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13893064
CY2016Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
122226
CY2018Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
102596164 shares
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9981044
CY2017Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
519461
CY2018Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1926371
CY2018Q1 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
2076766
CY2018Q1 us-gaap Assets Current
AssetsCurrent
78935997
CY2018Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
558260
CY2018Q1 us-gaap Accrued Rent Noncurrent
AccruedRentNoncurrent
150395
CY2018Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
167184
CY2018Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
208426045
CY2018Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
805023
CY2018Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-21826
CY2018Q1 us-gaap Assets
Assets
79128255
CY2018Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
58342578
CY2018Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
58423265
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19600591
CY2018Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
54548
CY2018Q1 us-gaap Liabilities
Liabilities
2881789
CY2018Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
79128255
CY2018Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2731394
CY2018Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
19136
CY2018Q1 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
150395
CY2018Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
51756
CY2018Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2018Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
992828
CY2018Q1 us-gaap Prepaid Rent
PrepaidRent
20981
CY2018Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q1 us-gaap Prepaid Insurance
PrepaidInsurance
501181
CY2018Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
183370
CY2018Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
350554
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-132260339
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3616662 shares
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6902500 shares
CY2018Q1 us-gaap Short Term Investments
ShortTermInvestments
58342578
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
76246466
CY2018Q1 cprx Prepaid Research Fee
PrepaidResearchFee
249094
CY2018Q1 cprx Accrued Non Clinical And Clinical Trial Expenses
AccruedNonClinicalAndClinicalTrialExpenses
990080
CY2018Q1 cprx Prepaid Precommercial Expenses
PrepaidPrecommercialExpenses
76900
CY2018Q1 cprx Accrued License Fees Current
AccruedLicenseFeesCurrent
278750
CY2018Q1 cprx Prepaid Subscription Fees
PrepaidSubscriptionFees
92916
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2320587
CY2017Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
2478043
CY2017Q4 us-gaap Assets Current
AssetsCurrent
85187157
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
227457
CY2017Q4 us-gaap Accrued Rent Noncurrent
AccruedRentNoncurrent
157456
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
159169
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
207421710
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1945575
CY2017Q4 us-gaap Assets
Assets
85387430
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57496702
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
102549498 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
102549498 shares
CY2017Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
8888
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
102549
CY2017Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
24011
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
821935
CY2017Q4 us-gaap Liabilities
Liabilities
4423618
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
85387430
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4266162
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
24035
CY2017Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
157456
CY2017Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
58281
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1173744
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Prepaid Insurance
PrepaidInsurance
638139
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
191385
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
350554
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-126560447
CY2017Q4 us-gaap Short Term Investments
ShortTermInvestments
26516711
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
80963812
CY2017Q4 cprx Prepaid Research Fee
PrepaidResearchFee
388977
CY2017Q4 cprx Accrued Non Clinical And Clinical Trial Expenses
AccruedNonClinicalAndClinicalTrialExpenses
970649
CY2017Q4 cprx Prepaid Precommercial Expenses
PrepaidPrecommercialExpenses
65000
CY2017Q4 cprx Accrued License Fees Current
AccruedLicenseFeesCurrent
252500
CY2017Q4 cprx Prepaid Subscription Fees
PrepaidSubscriptionFees
23347
cprx Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
1.00 pure
CY2018Q1 dei Amendment Flag
AmendmentFlag
false
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6902500 shares
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
971340
CY2018Q1 us-gaap Availableforsale Securities Gross Unrealized Gain Loss1
AvailableforsaleSecuritiesGrossUnrealizedGainLoss1
21826
CY2018Q1 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2018Q1 us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
80687
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-37896111
CY2018Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5721718
CY2018Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018Q1 us-gaap Depreciation
Depreciation
8015
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
CY2018Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2018Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018Q1 dei Document Type
DocumentType
10-Q
CY2018Q1 dei Document Period End Date
DocumentPeriodEndDate
2018-03-31
CY2018Q1 dei Entity Registrant Name
EntityRegistrantName
CATALYST PHARMACEUTICALS, INC.
CY2018Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001369568
CY2018Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2674398
CY2018Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5699892
CY2018Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1140552
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-401277
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-180916
CY2018Q1 us-gaap Nature Of Operations
NatureOfOperations
<div> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr style="page-break-inside:avoid"> <td width="8%" valign="top" align="left"><b>1.</b></td> <td align="left" valign="top"><b>Organization and Description of Business.</b></td> </tr> </table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"> Catalyst Pharmaceuticals, Inc. (the Company) is a development-stage biopharmaceutical company focused on developing and commercializing innovating therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndromes (CMS), MuSK antibody positive myasthenia gravis, and infantile spasms.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"> Since inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, acquiring operating assets and raising capital. The Company&#x2019;s primary focus is on the development and commercialization of its drug candidates. The Company has incurred operating losses in each period from inception through March&#xA0;31, 2018. The Company has been able to fund its cash needs to date through several public and private offerings of its common stock and warrants, through government grants, and through an investment by a strategic purchaser. See Note 10.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b><i>Capital Resources</i></b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"> While there can be no assurance, based on currently available information, the Company estimates that it has sufficient resources to support its operations for at least the next 12 months.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"> The Company may raise additional funds in the future, if required for its business, through public or private equity offerings, debt financings, corporate collaborations, governmental research grants or other means. The Company may also seek to raise new capital to fund additional product development efforts, even if it has sufficient funds for its planned operations. Any sale by the Company of additional equity or convertible debt securities could result in dilution to the Company&#x2019;s current stockholders. There can be no assurance that any required additional funding will be available to the Company at all or available on terms acceptable to the Company. Further, to the extent that the Company raises additional funds through collaborative arrangements, it may be necessary to relinquish some rights to the Company&#x2019;s drug candidates or grant sublicenses on terms that are not favorable to the Company. If the Company is not able to secure additional funding when needed, the Company may have to delay, reduce the scope of, or eliminate one or more research and development programs, which could have an adverse effect on the Company&#x2019;s business.</p> </div>
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-31847693
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-6081450
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
5933440
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
33032
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-5699892
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5933440
CY2018Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-21826
CY2018Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-21826
CY2018Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
233548
CY2018Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
31847693
CY2018Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div><b>n.</b> <table> <tr> <td valign="top" align="left"><b>RECLASSIFICATIONS.</b> Certain prior year amounts in the consolidated financial statements have been reclassified to conform to the current year presentation.</td> </tr> </table> </div>
CY2018Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
33032
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3259042
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
971340
CY2018Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
0.79
CY2018Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
4.64
CY2018Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
33032
CY2018Q1 dei Trading Symbol
TradingSymbol
CPRX
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
102557350 shares
CY2018Q1 us-gaap Use Of Estimates
UseOfEstimates
<div><b>c.</b> <table> <tr> <td valign="top" align="left"><b>USE OF ESTIMATES.</b> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</td> </tr> </table> </div>
CY2018Q1 cprx Maximum Maturity Period Of Cash And Cash Equivalent
MaximumMaturityPeriodOfCashAndCashEquivalent
Three months
CY2018Q1 cprx Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
1.00 pure
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8522663 shares
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3912020
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4967129
us-gaap Depreciation
Depreciation
12958
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
397235
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
397235
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1865942
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4967129
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-15248
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-178917
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-118082
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-33145
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3878875
us-gaap Operating Expenses
OperatingExpenses
4679871
us-gaap Net Income Loss
NetIncomeLoss
-4967129
us-gaap Operating Income Loss
OperatingIncomeLoss
-4679871
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
109977
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
33145
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2813929
us-gaap Share Based Compensation
ShareBasedCompensation
754144
us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
0.47
us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
4.64
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
82972316 shares

Files In Submission

Name View Source Status
0001193125-18-157513-index-headers.html Edgar Link pending
0001193125-18-157513-index.html Edgar Link pending
0001193125-18-157513.txt Edgar Link pending
0001193125-18-157513-xbrl.zip Edgar Link pending
cprx-20180331.xml Edgar Link completed
cprx-20180331.xsd Edgar Link pending
cprx-20180331_cal.xml Edgar Link unprocessable
cprx-20180331_def.xml Edgar Link unprocessable
cprx-20180331_lab.xml Edgar Link unprocessable
cprx-20180331_pre.xml Edgar Link unprocessable
d556138d10q.htm Edgar Link pending
d556138dex311.htm Edgar Link pending
d556138dex312.htm Edgar Link pending
d556138dex321.htm Edgar Link pending
d556138dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending